Testing low-cost brain scan markers for early Alzheimer and Parkinson disease
Tests brain scans to find early signs of Alzheimer or Parkinson disease in adults.
Key facts
- Who runs it
- Rennes University Hospital
- Where
- Rennes, FranceSee the site
- Trial code
- Registry title
- Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity
- Status
- Recruiting
- People taking part
- 120 people, planned
- Started
- 6 Nov 2023
- Expected to end
- Dec 2026
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- fMRI
- CONFMEM
- Record updated
- 5 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 to 80 who are healthy volunteers or have early Alzheimer's disease or Parkinson's disease, to test new brain-scan markers.
- Age
- 50 to 80 years
- Sex
- All sexes
- Disease stage
- Groups: people with subjective cognitive decline-plus, mild cognitive impairment due to Alzheimer's disease, newly diagnosed Parkinson's disease without cognitive problems, or Parkinson's disease with mild cognitive impairment. Healthy volunteers can also join.
Main reasons for not taking part
- Cannot have an MRI (for example pacemaker, defibrillator, metal implants, claustrophobia)
- Pregnant or breast-feeding women
- Adults under legal protection and people deprived of liberty
- Patients: dementia, or a score above 2 on the modified Hachinski scale
- Healthy volunteers: cognitive impairment (MoCA score below 26)
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- For all participants:
- French mother tongue
- right-handed
- with a level of education equal to or higher than the Certificat d'Études Primaires (Primary School Certificate)
- Free of any medical or psychiatric condition likely to interfere with cognition (excluding diagnosis for patients)
- Affiliated with a social security scheme
- Having received oral and written information about the protocol and having signed a consent form to participate in this research; DCS+ group:
- Meeting the diagnostic criteria for "subjective cognitive decline-plus" (Jessen criteria (Jessen et al., 2014); Alzheimer's patients "Mild Cognitive Impairment due to Alzheimer's Disease," "MCI-MA":
- Meeting the diagnostic criteria for "Mild neurocognitive disorder due to Alzheimer's disease" (criteria of (Albert et al., 2011)); De novo" Parkinsonian patients, "MPdn":
- Presenting with newly diagnosed ("de novo") Parkinson's disease and free of cognitive deficits (criteria of Postuma et al., 2015 (Postuma et al., 2015)); Parkinsonian patients with "Mild Cognitive Impairment, "MCI-MP":
- Presenting Parkinson's disease associated with "mild neurocognitive impairment" (criteria of Litvan et al., 2012 (Litvan et al., 2012))
Who cannot take part
- Cochlear implants
- Dementia according to McKhann criteria (McKhann et al., 2011)
- Cognitive impairment (MoCA score < 26)
- All participants (healthy volunteers and patients)
- Contraindications to MRI :
- Abdominal circumference + upper limbs sticking to the body > 200 cm
- Implantable pacemaker or defibrillator
- Neurosurgical clips
- Neural or peripheral stimulator
- Intra-orbital or encephalic metallic foreign bodies
- Endoprostheses fitted less than 4 weeks ago and osteosynthesis devices fitted less than 6 weeks ago
- Claustrophobia
- Pregnant or breast-feeding women
- Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty; Patients only
- Score >2 on the modified Hachinski scale (Hachinski et al., 2012)
- Sensory deficit interfering with experimental tests; Healthy volunteers only
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Where in France
- CHU RennesRennes, FranceContact: Pierre-Yves JONINTaking people
About the trial
What the trial wants to find out
The aim of the NODAL clinical trial is to demonstrate the feasibility of new, low-cost, non-invasive biomarkers of neurodegenerative pathologies as early Alzheimer and Parkinson, based on the estimation of the multimodal connectome.
The 5 groups in the trial
- DCS+Treatment being tested
Patient with subjective cognitive decline, prodromal condition of Alzheimer's disease
Treatment: fMRI and CONFMEM
- TCL-MATreatment being tested
Patient with mild neurocognitive disorder linked to Alzheimer's disease
Treatment: fMRI and CONFMEM
- MPdnTreatment being tested
early-stage or de novo Parkinson's disease patients with no cognitive deficits
Treatment: fMRI and CONFMEM
- TCL-MPTreatment being tested
Patient with mild neurocognitive disorder linked to Parkinson's disease
Treatment: fMRI and CONFMEM
- Healthy volunteersExisting treatment, for comparison
Treatment: fMRI and CONFMEM
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity
- Plain-language title
- Testing low-cost brain scan markers for early Alzheimer and Parkinson diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06080659, who can take part
- Record updated
- 5 January 2026